FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319027535> ?p ?o ?g. }

• W4319027535 endingPage "121" @default.
• W4319027535 startingPage "121" @default.
• W4319027535 abstract "Background: Intravesical injection of Botulinum toxin A (BoNT-A) and platelet-rich plasma (PRP) have been reported to alleviate bladder pain and decrease nocturia in patients with refractory interstitial cystitis/bladder pain syndrome (IC/BPS). Both treatments are novel and there has no comparison between them. This study compared the therapeutic effects and adverse events between IC/BPS patients receiving PRP or BoNT-A injections. Materials and Methods: This study retrospectively analyzed female patients with IC/BPS who were refractory to conventional treatment and received BoNT-A (n = 26) or PRP (n = 30) injections within the previous two years. Patients were arbitrarily treated with four monthly injections of PRP or a single injection of 100 U of BoNT-A. All injections were followed by cystoscopic hydrodistention. The primary endpoint was the global response assessment (GRA), and secondary endpoints were changes in the O’Leary-Sant IC symptom score, visual analog score (VAS) of bladder pain, voiding diary, and uroflow measures from baseline to six months after the first injection day. Results: The baseline demographics revealed no significant difference between groups. The GRA at one, three, and six months was similar between groups. A significant improvement in IC symptom scores was noted in both groups. Although VAS was significantly improved in overall patients, no significant difference was noted between the PRP and BoNT-A groups at 6 months. Only half of the study cohort had a GRA ≥2 at six months. An increase in the post-void residual was noted one month after the BoNT-A injection, but there was no difference between groups at three and six months. More patients reported dysuria (19.2% vs. 3.3%, p = 0.086) and urinary tract infection (UTI, 15.4% vs. 0%, p = 0.041) after BoNT-A injection than after the PRP injections. The time from the first injection to receiving alternative treatment was similar between groups. Conclusion: Both intravesical PRP and BoNT-A injections have similar efficacy in IC symptom improvement. However, only half of the study cohort had a GRA of ≥2 at the six-month follow-up BoNT-A injection carries a potential risk of UTI after treatment." @default.
• W4319027535 created "2023-02-03" @default.
• W4319027535 creator A5027013843 @default.
• W4319027535 creator A5053694613 @default.
• W4319027535 creator A5053860923 @default.
• W4319027535 date "2023-02-02" @default.
• W4319027535 modified "2023-10-14" @default.
• W4319027535 title "Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment" @default.
• W4319027535 cites W106102170 @default.
• W4319027535 cites W1503571030 @default.
• W4319027535 cites W1623121663 @default.
• W4319027535 cites W1695328506 @default.
• W4319027535 cites W1781773981 @default.
• W4319027535 cites W1792198273 @default.
• W4319027535 cites W184342154 @default.
• W4319027535 cites W1963789935 @default.
• W4319027535 cites W1967312126 @default.
• W4319027535 cites W1987667249 @default.
• W4319027535 cites W2007069784 @default.
• W4319027535 cites W2023903216 @default.
• W4319027535 cites W2030947359 @default.
• W4319027535 cites W2031151714 @default.
• W4319027535 cites W2036156711 @default.
• W4319027535 cites W2058225507 @default.
• W4319027535 cites W2063928696 @default.
• W4319027535 cites W2081899465 @default.
• W4319027535 cites W2090247886 @default.
• W4319027535 cites W2102209771 @default.
• W4319027535 cites W2106949446 @default.
• W4319027535 cites W2115946392 @default.
• W4319027535 cites W2129290564 @default.
• W4319027535 cites W2130075541 @default.
• W4319027535 cites W2145282371 @default.
• W4319027535 cites W2167138924 @default.
• W4319027535 cites W2293865433 @default.
• W4319027535 cites W2297351061 @default.
• W4319027535 cites W2321192065 @default.
• W4319027535 cites W2410475572 @default.
• W4319027535 cites W2905740602 @default.
• W4319027535 cites W3015493096 @default.
• W4319027535 cites W3037768982 @default.
• W4319027535 cites W3087637361 @default.
• W4319027535 cites W3091562419 @default.
• W4319027535 cites W4206037826 @default.
• W4319027535 cites W4221069183 @default.
• W4319027535 cites W4280523923 @default.
• W4319027535 doi "https://doi.org/10.3390/toxins15020121" @default.
• W4319027535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36828435" @default.
• W4319027535 hasPublicationYear "2023" @default.
• W4319027535 type Work @default.
• W4319027535 citedByCount "1" @default.
• W4319027535 countsByYear W43190275352023 @default.
• W4319027535 crossrefType "journal-article" @default.
• W4319027535 hasAuthorship W4319027535A5027013843 @default.
• W4319027535 hasAuthorship W4319027535A5053694613 @default.
• W4319027535 hasAuthorship W4319027535A5053860923 @default.
• W4319027535 hasBestOaLocation W43190275351 @default.
• W4319027535 hasConcept C121332964 @default.
• W4319027535 hasConcept C126322002 @default.
• W4319027535 hasConcept C126894567 @default.
• W4319027535 hasConcept C141071460 @default.
• W4319027535 hasConcept C142424586 @default.
• W4319027535 hasConcept C142724271 @default.
• W4319027535 hasConcept C197934379 @default.
• W4319027535 hasConcept C203092338 @default.
• W4319027535 hasConcept C204787440 @default.
• W4319027535 hasConcept C2777333188 @default.
• W4319027535 hasConcept C2777478456 @default.
• W4319027535 hasConcept C2778508898 @default.
• W4319027535 hasConcept C2778941218 @default.
• W4319027535 hasConcept C2780076745 @default.
• W4319027535 hasConcept C2909931192 @default.
• W4319027535 hasConcept C42219234 @default.
• W4319027535 hasConcept C535046627 @default.
• W4319027535 hasConcept C71924100 @default.
• W4319027535 hasConcept C77411442 @default.
• W4319027535 hasConcept C87355193 @default.
• W4319027535 hasConcept C89560881 @default.
• W4319027535 hasConceptScore W4319027535C121332964 @default.
• W4319027535 hasConceptScore W4319027535C126322002 @default.
• W4319027535 hasConceptScore W4319027535C126894567 @default.
• W4319027535 hasConceptScore W4319027535C141071460 @default.
• W4319027535 hasConceptScore W4319027535C142424586 @default.
• W4319027535 hasConceptScore W4319027535C142724271 @default.
• W4319027535 hasConceptScore W4319027535C197934379 @default.
• W4319027535 hasConceptScore W4319027535C203092338 @default.
• W4319027535 hasConceptScore W4319027535C204787440 @default.
• W4319027535 hasConceptScore W4319027535C2777333188 @default.
• W4319027535 hasConceptScore W4319027535C2777478456 @default.
• W4319027535 hasConceptScore W4319027535C2778508898 @default.
• W4319027535 hasConceptScore W4319027535C2778941218 @default.
• W4319027535 hasConceptScore W4319027535C2780076745 @default.
• W4319027535 hasConceptScore W4319027535C2909931192 @default.
• W4319027535 hasConceptScore W4319027535C42219234 @default.
• W4319027535 hasConceptScore W4319027535C535046627 @default.
• W4319027535 hasConceptScore W4319027535C71924100 @default.
• W4319027535 hasConceptScore W4319027535C77411442 @default.
• W4319027535 hasConceptScore W4319027535C87355193 @default.

• next